Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune, Inflammatory, and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD119 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD119 (IFNGR1) ECD-Fc Recombinant Protein High purity (>95%), Endotoxin controlled (<1.0 EU/μg). Sequence Verified. HEK293 expressed for native glycosylation. |
View CD119 Products |
| Gene Delivery | CD119 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional signaling assays. |
View CD119 Products |
| Benchmark Ab | Anti-CD119 Recombinant Antibody Recombinant positive control derived from benchmark research sequences for blocking/neutralization assays. |
View CD119 Products |
| Validator | CD119 siRNA Set Target-specific siRNA knockdown pool for specificity and functional validation. |
View CD119 Products |
| Related Target A | IFNGR2 The beta-chain accessory factor required for transducing the IFN-gamma signal post-CD119 binding. |
View IFNGR2 Products |
| Related Target B | IFNG (IFN-gamma) The primary pro-inflammatory cytokine ligand that initiates receptor dimerization and downstream JAK/STAT activation. |
View IFNG Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Cynomolgus, and Mouse CD119 ortholog proteins available with >95% purity to support cross-reactivity profiling. |
| Epitope shielding by native glycosylation | HEK293 mammalian expression system ensures correct post-translational modifications and native folding. |
| Lack of positive control references | Sequence-verified clinical-grade benchmark antibodies included in the catalog as reference standards. |
| Off-target assay noise | Validated siRNA sets and high-specificity negative control assays minimize false-positive discoveries. |
Live CD119 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD119 (IFNGR1) therapeutics is intensifying, with major players shifting focus from traditional systemic cytokine modulation to targeted receptor blockade and signaling regulation. As first-generation therapies targeting IFN-gamma (such as emapalumab) validate the pathway in hyper-inflammatory conditions like Hemophagocytic Lymphohistiocytosis (HLH), the next wave of R&D is targeting CD119 to achieve more localized control over IFN-gamma signaling. Future trends point toward bispecific antibodies locking CD119 with synergistic immune checkpoints, as well as small-molecule inhibitors disrupting the CD119/IFNGR2 dimerization interface.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAb | Novartis, Sobi, Academic Institutions | HLH, Severe Cytokine Release Syndrome (CRS) | Blocking Assay (Requires high-purity CD119 ECD-Fc to compete with ligand binding) |
| Bispecific/Multispecific | Biotech Startups, Immuno-oncology Pioneers | Solid Tumors, Autoimmune Diseases | Dimerization & Co-engagement Validation (Requires highly stable recombinant IFNGR1/IFNGR2 proteins) |
| Small Molecule (Protein-Protein Interaction) | Pharmaceutical Innovators | Inflammatory Bowel Disease (IBD), Lupus | High-Throughput Screening (Requires sequence-verified, endotoxin-controlled target proteins) |